Anti-angiogenic therapies, such as those based on vascular endothelial growth factor (VEGF) inhibitors, have been developed to inhibit tumor angiogenesis and normalize the abnormal vasculature in the TME [36,37]. The gene discussed is VEGFA; the disease is neoplasm.